Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q16637: Variant p.Asp30Asn

Survival motor neuron protein
Gene: SMN2
Feedback?
Variant information Variant position: help 30 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Asparagine (N) at position 30 (D30N, p.Asp30Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In SMA2. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 30 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 294 The length of the canonical sequence.
Location on the sequence: help GGVPEQEDSVLFRRGTGQSD D SDIWDDTALIKAYDKAVASF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASF

                              GGLPEPEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASF

Mouse                         ---SEQEDTVLFRRGTGQSDDSDIWDDTALIKAYDKAVASF

Rat                           G--SEQEDTVLFRRGTGQSDDSDIWDDTALIKAYDKAVASF

Bovine                        GGFPEPEDSVLFRRGTGESDDSDVWDDTALIKAYDKAVASF

Cat                           SGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASF

Drosophila                    ---------------MSDETNAAVWDDSLLVKTYDESVGLA

Fission yeast                 ----------------MDQSQKEVWDDSELRNAFETALHEF
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 294 Survival motor neuron protein
Region 1 – 32 Disordered
Region 26 – 51 Interacts with GEMIN2
Modified residue 25 – 25 Phosphothreonine
Modified residue 28 – 28 Phosphoserine
Modified residue 31 – 31 Phosphoserine
Mutagenesis 34 – 34 W -> A. Impairs GEMIN2 binding.
Mutagenesis 39 – 39 L -> A. Impairs GEMIN2 binding.
Mutagenesis 43 – 43 Y -> A. Impairs GEMIN2 binding.
Mutagenesis 44 – 44 D -> A. Impairs GEMIN2 binding.
Mutagenesis 46 – 46 A -> N. Impairs GEMIN2 binding.



Literature citations
Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y.; Grimmler M.; Schwarzer V.; Schoenen F.; Fischer U.; Wirth B.;
Hum. Mutat. 25:64-71(2005)
Cited for: VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95; GLY-111; GLY-262; CYS-272 AND ILE-274; CHARACTERIZATION OF VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95 AND GLY-111;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.